Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 1
2003 5
2004 7
2005 12
2006 4
2007 2
2008 5
2009 8
2010 6
2011 4
2012 4
2013 9
2014 7
2015 10
2016 5
2017 7
2018 7
2019 4
2020 4
2021 10
2022 15
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
"Ant-egg" cataract revisited.
Clemmensen K, Enghild JJ, Ivarsen A, Riise R, Vorum H, Heegaard S. Clemmensen K, et al. Among authors: vorum h. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):119-125. doi: 10.1007/s00417-016-3539-z. Epub 2016 Nov 5. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 27817115
Analytical platforms in vitreoretinal proteomics.
Cehofski LJ, Mandal N, Honoré B, Vorum H. Cehofski LJ, et al. Among authors: vorum h. Bioanalysis. 2014;6(22):3051-66. doi: 10.4155/bio.14.227. Bioanalysis. 2014. PMID: 25496257 Review.
A review of risk factors for retinal vein occlusions.
Ørskov M, Vorum H, Bjerregaard Larsen T, Vestergaard N, Lip GYH, Bek T, Skjøth F. Ørskov M, et al. Among authors: vorum h. Expert Rev Cardiovasc Ther. 2022 Sep;20(9):761-772. doi: 10.1080/14779072.2022.2112667. Epub 2022 Aug 19. Expert Rev Cardiovasc Ther. 2022. PMID: 35972726 Review.
144 results